I
n patients with ischemic cardiomyopathy (ICM), ventricular tachycardia (VT) is associated with poor long-term outcomes. 1 Three secondary prevention studies have shown the unequivocal benefit of implantable cardioverter-defibrillators (ICD) in patients with previous myocardial infarction and impaired left ventricular ejection fraction. [2] [3] [4] These studies, however, excluded patients with stable VT or with left ventricular ejection fraction >40%. Analysis from the antiarrhythmics versus implantable defibrillators registry, 5 however, suggests that clinically well-tolerated VT carries a poor prognosis as well. ICDs are therefore recommended in patients with previous myocardial infarction and sustained VT. 6 Although ICDs improve overall survival, they do not eliminate the substrate responsible for sustained arrhythmia. ICD without ablation carries a higher risk of shocks, 7, 8 and shocks are associated with decreased quality of life and increased mortality. 9 VT ablation, on the contrary, reduces or even abolishes VT episodes in some patients. Currently, guidelines suggest that VT ablation to be used as an adjunct to ICD. 10 It is not known whether some patients presenting with VT can be treated by ablation alone.
In our center, we have been routinely performing VT ablation as a first-line treatment in patients with ICM presenting with VT. Patients with a successful ablation, defined as the noninducibility of all VTs at the end of the index procedure followed by a negative electrophysiological study (EPS) within 3 months, do not have an ICD implanted. The aim of this study was, therefore, to evaluate this stepwise approach to VT management by comparing the long-term outcomes of those who received an ICD with those who did not.
Methods

Study Population
Between January 2002 and April 2011, a total of 189 patients with structural heart disease underwent 259 VT ablations in our center: 145 with ischemic cardiomyopathy (ICM), 17 with dilated cardiomyopathy, and 18 with arrythmogenic right ventricular dysplasia. In this study, we included patients with the following criteria: (1) previous history of myocardial infarct, (2) documented monomorphic VT, (3) no prior ICD, (4) repeat or planned EPS after first procedure, and (5) follow-up of at least 1 year after ablation or until censoring at the time of death. Patients were excluded if initial presentation was cardiac arrest, or patients with severe comorbidities where a clinical decision was made not to implant an ICD. Of the 145 patients with ICM, 74 did not have an ICD before VT ablation, and 45 fulfilled the criteria for the study. All patients provided informed consent, and all procedures were conformed to the CHU-Nancy guidelines.
EPS, Mapping, and Ablation
EPS, mapping, and catheter ablation were performed as previously described. 11 Briefly, a bipolar catheter was inserted via the femoral vein and positioned at the right ventricular apex and used primarily for VT induction with the application of up to 3 extrastimuli during spontaneous rhythm and then during paced rhythm (600-ms and then 400-ms basic cycle length). This programmed electric stimulation protocol was delivered through an external stimulator (Biotronik UHS 20, Biotronik Inc) with a 2-ms pulse width at twice the diastolic threshold. Failure to induce a sustained VT promoted the same protocol in the right ventricular outflow tract.
An 8F or 7F, 8 mm-tip or 3.5 mm-irrigated tip catheter (NAVI-STAR or THERMOCOOL, Biosense-Webster, Johnson & Johnson) was used for mapping and ablation of VT circuits. Access to the left ventricle was achieved retrogradely across the aortic valve or through transatrial septal puncture.
The electric reference was chosen as a morphologically stable and regular ventricular electrogram that was obtained from either an endocardial or surface lead, with the choice determined by a QRS complex with a sharp apex and a strong positive (or negative) deflection during VT. The width of the window of interest varied from 1 VT map to another, inasmuch as it was correlated with the VT cycle length with the following formula: window of interest width = VT cycle length−20 ms. The middle of the window of interest was selected to coincide with the electric reference. The local activation time for each endocardial position under the mapping catheter was calculated as the interval between the electric reference and the peak deflection of the mapping bipolar electrogram. In case of double potentials, the earliest peak deflection of the doublet was used. Long-duration fractionated electrograms were marked to the highest peaklet.
The left ventricle was plotted during the induced clinical VT by dragging the catheter over the endocardium. In case of a VT with a right ventricular septal exit, the right ventricle was mapped as well to check whether the VT isthmus, or a part of it, was located in the right ventricle. Infarct regions were sought first, and more data points (target filling threshold set to 10) were acquired in and around these areas. Refining the area under investigation relied on the usual clinical indicators, such as sinus rhythm analysis, echocardiography, and VT morphology, on the 12-lead ECG. More data points were acquired in the zones defined as scarified, with low-amplitude potentials, with diastolic electrograms, or with double potentials. These areas were probed because they are important for the identification of the reentrant circuit. The mapping procedure was terminated when a density of points was achieved that was sufficient enough to allow an understanding of the VT circuit. The resulting reentrant circuit was considered to be the spatially shortest route of unidirectional activation encompassing a full range of mapped activation times (>90% of the tachycardia cycle length) and returning to the site of earliest activation. Conventional mapping, including pace mapping during sinus rhythm, entrainment maneuvers, and postpacing interval analysis 12 during VT, were not performed routinely because VT isthmus definition was based on VT activation time mapping. Once defined, linear radiofrequency (RF) lesions were placed so as to transect the VT isthmus in case of mappable VTs. For unmappable VTs, ablation sites were required to have abnormal low-amplitude electrograms, electrograms with double potentials, wide fractionated potentials, or isolated late potentials during sinus or paced rhythm. Pacemapping during sinus rhythm and measurement of the stimulus-to-QRS interval were then used to unmask VT isthmuses and determine ablation sites 13 of unmappable VTs. Systemic anticoagulation was achieved with heparin (initial bolus of 50 U/kg IV followed by 1000-2000 U/h) throughout the procedure. Sedation was obtained with 10 mg IV nalbuphine, with incremental doses at 5 mg as necessary.
RF Ablation and End Point
Identification of the ablation site was based on analysis of the 3D map. The anode was a 575-cm 2 back plate placed under the patient's left shoulder. RF ablation was performed with a 550-kHz RF Stockert-Cordis generator. The RF energy was delivered in a temperature-controlled mode for 60 to 120 seconds at each ablation site with a maximal temperature/power target of 45°C/40 W for 3.5-mm tips (55°C/75 W for 8-mm tips). Acute success was defined as a negative EPS at the end of the procedure. Successful VT ablation was defined as acute success and a negative repeat EPS at 2 to 3 months. Negative EPS was defined as absence of inducibility of any sustained monomorphic VT with a rate <270/min. Induction of monomorphic very fast VT (rate ≥270/min) as well as polymorphic VT or ventricular fibrillation were not defined as positive EPS.
Management After Ablation
After ablation, patients were monitored for 72 hours by telemetry. Transthoracic echocardiography was performed within 2 days after ablation. Patients were then discharged and followed on an outpatient basis, with clinical evaluation and 24-hour Holter recordings performed regularly.
All patients were evaluated routinely at 6 to 8 weeks postprocedure and at 3-to 6-month intervals. Patients with ICD underwent interrogation every 6 months, and all recorded arrhythmic episodes were collected and analyzed. Follow-up data, including mortality, were available on all patients.
Stepwise Approach Algorithm
All patients underwent VT ablation with the primary aim of complete abolition of all VTs. After a successful procedure, an EPS was performed at 3 months and further ablation was carried on if VT was induced. Before this repeat EPS, antiarrhythmic drugs were withdrawn for at least 5 half-lives in all patients, except amiodarone which was stopped at least 1 month before. Repeat EPS was continued after a successful ablation until the study was negative or an ICD was implanted. The stepwise algorithm is shown in Figure 1 . ICD was implanted if any of the following criteria was present:
1. Ejection fraction ≤35% in patients who underwent VT ablation after the publication of the European Society of Cardiology Guidelines 6 for ICD implantation (ie, patients with ejection fraction <35% who underwent VT ablation before this publication did not receive an ICD if they had successful ablation). 2. A fast VT (VT with a shorter cycle length than the clinical VT) was inducible at the end of the procedure. 
Statistical Analysis
Results
Patient Characteristics
The study population consists of 45 patients (mean age, 65.2±9.6 years; 91% men) with a previous history of myocardial infarction (Table 1) . Thirty-two patients (71.1%) had a previous inferior myocardial infarction and the left ventricular ejection fraction was 40% (interquartile range, 30%-50%). Twentyseven patients (60%) presented with a combination of shortness of breath or palpitations, 6 (13.3%) with chest pain, 5 (11.1%) with syncope, 1 (2.2%) with cardiogenic shock, and the rest with a combination of these. The median VT cycle length was 370 ms at presentation and varied from 240 to 664 ms. Table 2 shows the characteristics of the different VTs during ablation.
Ablation Results
Success was obtained in 40 patients (88.9%) after first ablation. Of the remaining 5 patients, 3 patients had fast VT at the end of the procedure and had an ICD implanted, and the other 2 patients had repeat EPS (Figure 1 ). At follow-up and before repeat EPS, 1 patient died of heart failure, and there was VT recurrence in 3 patients(7.5%). Repeat EPS was performed in 36 patients, and VT was inducible in 13 patients (36.1%). For patients with a negative EPS, 1 (4.5%) had recurrent VT. On the basis of our algorithm, ICD was implanted in 19 patients (42.2%). Complications occurred in 4 patients, including 2 cerebrovascular accidents, 1 femoral hematoma, and 1 complete heart block.
ICD Therapies and Mortality
During a median follow-up of 4.5 years (interquartile range, 2.1-7.0), there were 5 deaths in the group without an ICD and 9 in the ICD group. Patients with an ICD had a lower median survival as compared to patients without an ICD, although the results were not statistically significant (log rank test, P=0.11; Figure 2 ). The mean age in the ICD versus no ICD group were 63.4±10.4 years versus 67.2±8.6 years, P=0.18, and median left ventricular ejection fraction (%) was 40 (30-44) versus 45 (30-50), P=0.21. ICD implantation was not associated with improved survival (unadjusted hazard ratio, 0.42 [0.14-1.25]; P=0.11). Using Cox regression analysis with age and ICD implantation as covariates, only age was an independent predictor of mortality (hazard ratio, 1.13; 95% confidence interval, 1.03-1.22; P=0.007), whereas ICD implantation was not (hazard ratio, 0.54; 95% confidence interval, 0.18-1.64; P=0.28). A similar trend was obtained when cardiovascular (CV) mortality (4 CV deaths in the group without an ICD and 6 in the ICD group) was compared ( Figure 3 ) between patients with and those without an ICD. The causes of CV deaths were as follows: (1) heart failure (3 in the no ICD group and 3 in the ICD group), (2) intractable VT or ventricular fibrillation (2 in the ICD group), (3) sudden death (1 in the no ICD group), and (4) cardiac tamponade after ICD implantation in 1 patient.
patients with monomorphic VT and no ICD Acute Success, n=40
Repeat EPS within 3 months, n=36
No VT Inducible, n=23
Recurrence of VT prior to EPS, n=3
Negative EPS n=1 VT inducible, n=13
Are all the VTs well tolerated?
Repeat Ablation n=6
Acute Success n=6
Repeat EPS, n=6
No VT Recurrence n=22
No VT inducible, n=1
Positive EPS n=5
Recurrence No ICD, n=22
Positive EPS n=1
Negative EPS n=1 Figure 1 . Stepwise approach to the management of patients with ischemic cardiomyopathy and ventricular tachycardia (VT). Well-tolerated VT was defined as VT without cardiovascular compromise (ie, presyncope, pulmonary edema, or cardiogenic shock) and with no requirement of an immediate DC cardioversion. EPS indicates electrophysiology study; and ICD, implantable cardioverter-defibrillator. April 2013
VT With Syncope or CV Compromise
A subgroup of patients (10/45) presented with VT with syncope or significant CV compromise (presyncope, pulmonary edema, or cardiogenic shock). They all underwent the same protocol of VT ablation and ablation-guided ICD implantation. The results of these patients are shown in Table 3 .
Arrhythmic Death
Two patients in the ICD group died as a result of intractable VT or ventricular fibrillation, and 1 patient in the group without ICD had a sudden death. He was a 76-year-old man, with a left ventricular ejection fraction of 50%, who initially presented with a VT cycle length of 353 ms and had an acutely successful ablation.
ICD Therapies
In patients with an ICD, therapy for VT was delivered in 8 of 19 patients (42.1%), with 7 patients having had ≥2 therapies.
Discussion
The aim of this study was to look at the results of a stepwise approach for the management of patients with ICM presenting with VT, with ablation as an initial treatment strategy. ICD was implanted based on a predefined decision tree taking into consideration acute success, inducibility at repeat EPS, and recurrence. To our knowledge, this is the first study to look at such an approach. This study has several interesting findings.
First, it suggests that a strategy of successful VT ablation, defined as noninducibility of all VTs followed by a negative EPS, in patients with postinfarct VT is safe, feasible, and can be used as a means to risk stratify patients as to the implantation of ICD. Second, the mortality rate in the successful ablation group was not higher than the ICD group. Although the numbers are limited, this strategy does not seem harmful even in patients presenting with hemodynamically unstable VT. In patients with ICM, VT carries a poor prognosis.
1,2,5
Various studies have shown the superiority of ICD therapy compared with medical therapy on long-term outcomes in such patients. [2] [3] [4] Devices, however, do not take away the arrhythmic substrate capable of sustaining a VT circuit. They merely provide therapy for fast heart rates, which the ICD recognizes as *Percentage of patients in whom VT entrainment and pacemapping during sinus rhythm were used to help unmask the VT isthmus.
†Percentage of patients in whom abolition of postsystolic potentials (recorded on sinus rhythm EGM) was performed in addition to VT isthmus transection. VT tolerance: Fair, VT without cardiovascular compromise; Poor, VT and cardiovascular compromise (ie, presyncope, pulmonary edema, or cardiogenic shock). AF indicates atrial fibrillation; CABG, coronary artery bypass grafting; ICD, intracardiac defibrillator; NYHA, New York Heart association; PTCA, percutaneous transluminal coronary angioplasty; and VT, ventricular tachycardia.
*Treatment at hospital discharge after the first procedure.
VT or ventricular fibrillation based on predefined algorithms. VT ablation, on the contrary, targets the substrate responsible for the arrhythmia mechanism. Two randomized control trials have shown that catheter ablation reduces ICD therapies, including shocks, 7, 8 in patients with ICM and VT. The question that arises therefore is whether a successful ablation is enough, at least in a subgroup of patients. One problem with successful VT ablation is the high rate of recurrence varying between 20% and 44%. [14] [15] [16] [17] [18] In a group of patients with ischemic heart disease and hemodynamically well-tolerated VT, Della Bella et al 14 showed that VT ablation resulted in the abolition of the targeted VT in 73% of patients. Although the recurrence rate was substantial (27%), only 3 patients (2.5%) died suddenly. Our study is similar to the study by Della Bella et al 14 in that we looked at a similar cohort of patients. However, in the above study, repeat VT stimulation study was not performed. Moreover, ICD was implanted in 11% in the study population before VT ablation. The same group 19 showed that a negative EPS after VT ablation for VT storm was a predictor of absence of VT recurrence over a long period of time. It is possible that incomplete ablation or edema might limit the predictive value of EPS immediately after ablation, and therefore it is possible that an EPS remote from the ablation time provide a better answer. In patients with a structural heart disease, Frankel et al 20 showed that a negative EPS performed 3.1±2.1 days after ablation predicted >80% VT-free survival over 1-year follow-up. We arbitrarily chose a 3-month period to allow the scar to mature. Our study therefore adds further to the current understanding. However, given the high-recurrence rates, additional substrate-based ablation might provide even better results.
There was a trend toward a survival benefit in the successful VT ablation group compared with the group with ICD, although the results were not statistically significant. Several trials have shown that ICD therapies are associated with mortality and morbidity, and therefore it is conceivable that successful ablation and abolition of substrate for sustained VT might lower mortality.
In addition, there is also an economic argument in favor of the stepwise approach to VT ablation. ICDs are costly, and therefore this strategy might allow us to use limited resources in a more cost-effective way.
Limitations
This study is not a randomized controlled trial, and therefore the inherent limitations of observational studies apply. Patient groups are not homogeneous. Decision on whether patients had an ICD was not random but based on a decision tree. It is therefore conceivable that the patient group without an ICD represented a less healthy cohort. However, the mortality difference demonstrated would argue against this. It can be argued that physicians may have felt more comfortable not implanting an ICD in certain patients and this would have created an inherent bias. However, this is unlikely, in our opinion, given that this decision was made on a predefined algorithm.
Second, it is a small study, and analysis of subgroups inherently makes the groups smaller.
Third, the exact timing of a repeat VT stimulation study to confirm noninducibility is unknown. We used a 3-month window based on experience.
Fourth, the only end point of the study was prevention of VT inducibility. Whether modification of the arrhythmia substrate was achieved cannot be proven.
Finally, the results of this observational study need to be verified in a randomized controlled trial. We appreciate that it may take a long time for such a randomized controlled trial to be performed, mainly because of the current guidelines. 
CLINICAL PERSPECTIVE
Implantable cardioverter-defibrillators (ICD) are recommended in patients with ventricular tachycardia (VT) late after myocardial infarction, and catheter ablation of VT is currently considered only as adjunctive therapy to decrease recurrent VT. Whether a successful VT ablation alone (without ICD implantation) might be a viable strategy for some patients is not known. We evaluated a stepwise approach for VT management in 45 postinfarct patients in whom catheter ablation was offered as a first-line therapy between 2002 and 2011. After acutely successful ablation, defined as absence of any inducible VT, repeat stimulation was performed 2 to 3 months later with further ablation for inducible VT. An ICD was implanted in 19 of 45 patients (42%) for whom VT inducible could not be abolished, or who were studied after 2006 and had left ventricular ejection fraction ≤35%. During a median follow-up of 4.5 years, mortality occurred in 14 of 45 patients (31.1%) and was not statistically different between the ICD and no ICD groups. There was 1 sudden death in the no ICD group. Our results suggest that a stepwise approach to the management of VT, with ablation as a first-line treatment in postinfarct patients presenting with VT, might be a reasonable option.
